Breast cancer subtype and screening sensitivity in the Quebec Mammography Screening Program

被引:5
作者
Perron, Linda [1 ]
Chang, Sue-Ling [2 ]
Daigle, Jean-Marc [1 ]
Vandal, Nathalie [1 ]
Theberge, Isabelle [1 ]
Diorio, Caroline [2 ]
Lemieux, Julie [2 ]
Pelletier, Eric [1 ]
Brisson, Jacques [2 ]
机构
[1] Inst Natl Sante Publ Quebec, Quebec City, PQ, Canada
[2] Univ Laval, CHU Quebec, Ctr Rech, Quebec City, PQ, Canada
关键词
Mass screening; mammography; breast cancer; cohort study; tumour biomarkers; screening sensitivity; RISK-FACTORS; PROGNOSTIC-FACTORS; AMERICAN SOCIETY; INTERVAL CANCERS; WOMEN; EXPRESSION; ASSOCIATION; BIOMARKERS; PHENOTYPE; THERAPY;
D O I
10.1177/0969141318816736
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objective In mammography screening, interval cancers present a problem. The metric 'screening sensitivity' monitors both how well a programme detects cancers and avoids interval cancers. To our knowledge, the effect of breast cancer surrogate molecular subtypes on screening sensitivity has never been evaluated. We aimed to measure the 2-year screening sensitivity according to breast cancer subtypes. Methods We studied 734 women with an invasive breast cancer diagnosed between 2003 and 2007 after participating in one regional division of Quebec's Mammography Screening Program. They represented 83% of all participating women with an invasive BC diagnosis in that region for that period. Tumours were categorized into 'luminal A-like', 'luminal B-like', 'triple-negative' and 'HER2-positive' subtypes. We used logistic regression and marginal standardization to estimate screening sensitivity, sensitivity ratios (SR) and sensitivity differences. We also assessed the mediating effect of grade. Results Adjusted 2-year screening sensitivity was 75.4% in luminal A-like, 66.1% in luminal B-like, 52.9% in triple-negative and 45.3% in HER2-positive, translating into sensitivity ratios of 0.88 (95% confidence interval [CI] = 0.78-0.98) for luminal B-like, 0.70 (CI = 0.56-0.88) for triple-negative and 0.60 (CI = 0.39-0.93) for HER2-positive, when compared with luminal A-like. Grade entirely mediated the subtype-sensitivity association for triple negative and mediated it partly for HER2-positive. Screening round (prevalent vs. incident) did not modify results. Conclusion There was substantial variation in screening sensitivity according to breast cancer subtypes. Aggressive phenotypes showed the lowest sensitivity, an effect that was mediated by grade. Tailoring screening according to women's subtype risk factors might eventually lead to more efficient programs.
引用
收藏
页码:154 / 161
页数:8
相关论文
共 40 条
  • [1] Comparison of methods for handling missing data on immunohistochemical markers in survival analysis of breast cancer
    Ali, A. M. G.
    Dawson, S. -J
    Blows, F. M.
    Provenzano, E.
    Ellis, I. O.
    Baglietto, L.
    Huntsman, D.
    Caldas, C.
    Pharoah, P. D.
    [J]. BRITISH JOURNAL OF CANCER, 2011, 104 (04) : 693 - 699
  • [2] [Anonymous], 2018, Breast Cancer Statistics
  • [3] [Anonymous], 2017, BREASTSCREEN AUSTR M
  • [4] Established breast cancer risk factors and risk of intrinsic tumor subtypes
    Barnard, Mollie E.
    Boeke, Caroline E.
    Tamimi, Rulla M.
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2015, 1856 (01): : 73 - 85
  • [5] Clinicopathological differences between interval and screen-detected breast cancers diagnosed within a screening programme in Northern Portugal
    Bento, Maria Jose
    Goncalves, Guilherme
    Aguiar, Ana
    Antunes, Luis
    Veloso, Vitor
    Rodrigues, Vitor
    [J]. JOURNAL OF MEDICAL SCREENING, 2014, 21 (02) : 104 - 109
  • [6] Measuring proliferation in breast cancer: practicalities and applications
    Beresford, Mark J.
    Wilson, George D.
    Makris, Andreas
    [J]. BREAST CANCER RESEARCH, 2006, 8 (06)
  • [7] Triple-negative breast cancer in the older population
    Boyle, P.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 7 - 12
  • [8] Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry
    Brewster, Abenaa M.
    Chavez-MacGregor, Mariana
    Brown, Powel
    [J]. LANCET ONCOLOGY, 2014, 15 (13) : E625 - E634
  • [9] Biological characteristics of interval cancers: a role for biomarkers in the breast cancer screening
    Caldarella, A.
    Puliti, D.
    Crocetti, E.
    Bianchi, S.
    Vezzosi, V.
    Apicella, P.
    Biancalani, M.
    Giannini, A.
    Urso, C.
    Zolfanelli, F.
    Paci, E.
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (02) : 181 - 185
  • [10] Canadian Partnership Against Cancer, 2017, COL CANC SCREEN CAN